Contents

Key findings of the INBUILD trial of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases

Please click the link below to download a plain language summary of the key findings of the INBUILD trial of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases.

Flaherty KR et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J 2021;2004538.

Header - Navigation Icon

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this plain language summary or the article on which it was based. Editorial support was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard, London, UK, which was contracted and funded by Boehringer Ingelheim. The authors were fully responsible for all content and editorial decisions, were involved at all stages of development and provided their approval on the final version. Boehringer Ingelheim was given the opportunity to review the manuscript and plain language summary for medical and scientific accuracy as well as intellectual property considerations.